| Name | Title | Contact Details |
|---|
MedAvante Inccvc is one of the leading companies in Healthcare, Pharmaceuticals, & Biotech industry. MedAvante Inccvc is based in Trenton, NJ. You can find more information on MedAvante Inccvc at www.medavante.net
The West Virginia Health Information Network (WVHIN) offers services that enable the secure electronic exchange of patient health information, providing benefits to health care providers, health care systems and patients. In February 2010, the West Virginia Department of Health and Human Resources received $7.8 million in federal funds as part of the State Health Information Exchange Cooperative Agreement Program. The West Virginia Health Information Network (WVHIN) is using these funds to launch WVHIN’s statewide electronic health information exchange services. In August 2011, the WVHIN chose Truven Health Analytics as its technical services partner. Together with Truven Health and its strategic partners, the WVHIN has made the electronic exchange of patient health information a reality for health care providers and patients across the State of West Virginia.
Abeona Therapeutics is focused on developing and delivering gene therapy and plasma-based products for severe and life-threatening rare diseases. Abeona’s lead program is an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome (MPS IIIA and IIIB) in collaboration with patient advocate groups, researchers and clinicians. Clinical trials for Sanfilippo types A and B are anticipated to begin in 2015.
Cardinal Analytx Solutions brings together distinguished innovators and leaders collaboratively advancing into new territory to substantially address one of the most pressing human and economic challenges of our time.
Discovery Laboratories, Inc. is a specialty biotechnology company focused on advancing a new standard in respiratory critical care. Discovery Labs` technology platform includes its novel proprietary KL4 surfactant, a synthetic, peptide-containing surfactant that is structurally similar to pulmonary surfactant, and its proprietary drug delivery technologies being developed to enable efficient delivery of aerosolized KL4 surfactant and other inhaled therapies. Discovery Labs` strategy is initially focused on neonatology and improving the management of respiratory distress syndrome (RDS) in premature infants. Discovery Labs believes that its RDS product portfolio has the potential to become the new standard of care for RDS and, over time, enable the treatment of a significantly greater number of premature infants who could benefit from surfactant therapy that are currently not being treated. In many pulmonary diseases, including RDS, acute lung injury (ALI), and other respiratory conditions, surfactant is either deficient or may fail to function properly. Our precision-engineered, peptide-containing KL4 surfactant has been designed to mimic the essential function of human pulmonary surfactant and may have the potential to address conditions such as these. We are developing our proprietary delivery technologies to one day enable efficient, targeted upper-respiratory or alveolar delivery of our KL4 surfactant in aerosolized form to allow for a gentler, less invasive delivery approach. These same delivery systems may also potentially be used to deliver a variety of additional aerosolized medicines safely and in a simplified way compared with the current standard of care.